(KMTS) Kestra Medical - Overview
Sector: Healthcare | Industry: Medical Instruments & Supplies | Exchange: NASDAQ (USA) | Market Cap: 1.263m USD | Total Return: -3.1% in 12m
Avg Turnover: 5.60M
Warnings
Share dilution 180.0% YoY
Interest Coverage Ratio -18.3 is critical
Altman Z'' -10.71 < 1.0 - financial distress zone
Fakeout Volatile
Tailwinds
No distinct edge detected
Kestra Medical Technologies (KMTS) is a healthcare equipment firm specializing in wearable medical devices and digital monitoring for cardiovascular disease. The company’s primary offering is the Cardiac Recovery System, which centers on the ASSURE WCD, a wearable cardioverter defibrillator designed to mitigate the risk of sudden cardiac arrest. This platform integrates therapeutic intervention with digital health services to facilitate patient oversight and engagement.
Operating within the medical technology sector, the company utilizes a business model focused on chronic disease management through connected hardware and data-driven support services. The wearable cardioverter defibrillator market serves as a critical niche for patients who are at high risk but may not yet be candidates for permanent implantable devices. Investors may find it useful to examine ValueRay for further data on the companys valuation metrics and market position.
Founded in 2014 and headquartered in Kirkland, Washington, Kestra focuses on the commercialization of intuitive medical technologies that bridge the gap between hospital-grade monitoring and at-home patient care. The integration of digital solutions into physical hardware allows for continuous data collection, which is a growing trend in the GICS Health Care Equipment sub-industry.
- ASSURE WCD market penetration drives core revenue growth in cardiac monitoring
- CMS reimbursement rate changes impact profitability of wearable cardioverter defibrillators
- Expansion of integrated digital health services improves long-term recurring revenue margins
- Competitive pressure from established medical device firms affects market share acquisition
- FDA regulatory compliance and product safety updates influence investor risk sentiment
| Net Income: -144.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.32 > 0.02 and ΔFCF/TA 50.42 > 1.0 |
| NWC/Revenue: 323.9% < 20% (prev 59.32%; Δ 264.5% < -1%) |
| CFO/TA -0.23 > 3% & CFO -86.7m > Net Income -144.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 7.32 > 1.5 & < 3 |
| Outstanding Shares: last quarter (52.8m) vs 12m ago 6.68% < -2% |
| Gross Margin: 48.75% > 18% (prev 0.34%; Δ 4.84k% > 0.5%) |
| Asset Turnover: 34.36% > 50% (prev 48.74%; Δ -14.38% > 0%) |
| Interest Coverage Ratio: -18.26 > 6 (EBITDA TTM -128.0m / Interest Expense TTM 7.46m) |
| A: 0.71 (Total Current Assets 314.1m - Total Current Liabilities 42.9m) / Total Assets 379.3m |
| B: -1.62 (Retained Earnings -613.0m / Total Assets 379.3m) |
| C: -0.56 (EBIT TTM -136.2m / Avg Total Assets 243.7m) |
| D: -6.07 (Book Value of Equity -554.7m / Total Liabilities 91.4m) |
| Altman-Z'' = -10.71 = D |
| DSRI: 1.01 (Receivables 12.7m/7.93m, Revenue 83.7m/52.6m) |
| GMI: 0.70 (GM 48.75% / 34.15%) |
| AQI: 0.48 (AQ_t 0.02 / AQ_t-1 0.04) |
| SGI: 1.59 (Revenue 83.7m / 52.6m) |
| TATA: -0.15 (NI -144.8m - CFO -86.7m) / TA 379.3m) |
| Beneish M = -3.33 (Cap -4..+1) = AA |
As of May 27, 2026, the stock is trading at USD 21.82 with a total of 289,393 shares traded.
Over the past week, the price has changed by +11.38%,
over one month by -1.84%,
over three months by -11.12% and
over the past year by -3.11%.
Kestra Medical has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy KMTS.
- StrongBuy: 4
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 27.7 | 27% |
P/S = 15.0882
P/B = 4.3863
Revenue TTM = 83.7m USD
EBIT TTM = -136.2m USD
EBITDA TTM = -128.0m USD
Long Term Debt = 42.3m USD (from longTermDebt, last quarter)
Short Term Debt = 10.0k USD (from shortTermDebt, last quarter)
Debt = 46.6m USD (corrected: LT Debt 42.3m + ST Debt 10.0k) + Leases 4.29m
Net Debt = -244.8m USD (calculated: Debt 46.6m - CCE 291.3m)
Enterprise Value = 1.02b USD (1.26b + Debt 46.6m - CCE 291.3m)
Interest Coverage Ratio = -18.26 (Ebit TTM -136.2m / Interest Expense TTM 7.46m)
EV/FCF = -8.49x (Enterprise Value 1.02b / FCF TTM -120.0m)
FCF Yield = -11.78% (FCF TTM -120.0m / Enterprise Value 1.02b)
FCF Margin = -143.3% (FCF TTM -120.0m / Revenue TTM 83.7m)
Net Margin = -173.0% (Net Income TTM -144.8m / Revenue TTM 83.7m)
Gross Margin = 48.75% ((Revenue TTM 83.7m - Cost of Revenue TTM 42.9m) / Revenue TTM)
Gross Margin QoQ = 52.57% (prev 50.63%)
Tobins Q-Ratio = 2.68 (Enterprise Value 1.02b / Total Assets 379.3m)
Interest Expense / Debt = 16.03% (Interest Expense 7.46m / Debt 46.6m)
Taxrate = 21.0% (US default 21%)
NOPAT = -107.6m (EBIT -136.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.32 (Total Current Assets 314.1m / Total Current Liabilities 42.9m)
Debt / Equity = 0.16 (Debt 46.6m / totalStockholderEquity, last quarter 288.0m)
Debt / EBITDA = 1.91 (negative EBITDA) (Net Debt -244.8m / EBITDA -128.0m)
Debt / FCF = 2.04 (negative FCF - burning cash) (Net Debt -244.8m / FCF TTM -120.0m)
Total Stockholder Equity = 210.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -59.44% (Net Income -144.8m / Total Assets 379.3m)
RoE = -17.59% (Net Income TTM -144.8m / Total Stockholder Equity 823.4m)
RoCE = -15.74% (EBIT -136.2m / Capital Employed (Equity 823.4m + L.T.Debt 42.3m))
RoIC = -46.87% (negative operating profit) (NOPAT -107.6m / Invested Capital 229.6m)
WACC = 10.65% (E(1.26b)/V(1.31b) * Re(10.58%) + D(46.6m)/V(1.31b) * Rd(16.03%) * (1-Tc(0.21)))
Discount Rate = 10.58% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 93.09 | Cagr: 127.9%
[DCF] Fair Price = unknown (Cash Flow -120.0m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.50 | # QB: 0
Revenue Correlation: 98.92 | Revenue CAGR: 180.0% | SUE: N/A | # QB: 0
EPS current Quarter (2026-07-31): EPS=-0.54 | Chg30d=+0.00% | Revisions=+0% | Analysts=2
[Analyst] Revisions Ratio: +0%